Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 15/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 14/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 7/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 6/20 | 1.00 |
| ▸ | CHRNB3 | Q05901 | 6/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.87 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.70 |
| ▸ | JAK2 | O60674 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4725367 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| Hydrochloric Acid SCHEMBL6585118 | 0.99 | CHRNB2 (0.98) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL14941055 | 0.93 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL14941054 | 0.93 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL6583548 | 0.90 | CHRNB2 (1.00) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| Hydrochloric Acid SCHEMBL6585308 | 0.89 | CHRNB2 (0.98) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL8305152 | 0.87 | CHRNB2 (0.77) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL12190816 | 0.87 | CHRNB2 (0.77) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL12190815 | 0.85 | CHRNB2 (0.81) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 | |
| SCHEMBL13308403 | 0.85 | CHRNB2 (0.74) | CHRNB2CHRNA3CHRNB4CHRNB1CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0934308-B1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2004-08-11 | — | — | EP | claimed |
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | claimed |
| US-9994548-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994548-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170107197-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-20170107197-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | disclosed |
| US-9346784-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-9346784-B2 | Phenyl-substituted nicotinic ligands, and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140323461-A1 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof | DUKE UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| US-20140323461-A1 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof | DUKE UNIVERSITY | 2014-10-30 | — | — | US | disclosed |
| US-8642612-B2 | Nicotinic desensitizers and methods of selecting, testing, and using them | POTOMAC PHARMACEUTICALS, INC. (US) | 2014-02-04 | — | — | US | disclosed |
| WO-2013071067-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES (US) | 2010-05-27 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008011484-A2 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | BETHESDA PHARMACOLOGY ASSOCIATES, LLC (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-0934308-B1 | 3-PYRIDYLOXYMETHYL HETEROCYCLIC ETHER COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LAB (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6437138-B1 | 5-BROMO-6-CHLORO-3-(2-(S)-AZETIDINYL OR PYRROLIDINYL-METHOXY) PYRIDINE INTERMEDIATES FOR THE 5-SUBSTITUTED COMPOUNDS WHICH ARE POTENT LIGANDS AT NEURONAL NICOTINIC CHOLINERGIC CHANNEL RECEPTORS, NEUROTRANSMITTER CONTROLLING AGENTS | ABBOTT LABORATORIES | 2002-08-20 | — | — | US | disclosed |
| US-6127386-A | STIMULANTS, NEUROTRANSMITTERS, CHOLINERGIC AGENTS | ABBOTT LABORATORIES (US) | 2000-10-03 | — | — | US | disclosed |
| US-5629325-A | TREATMENT OF NERVOUS SYSTEM DISORDERS; NEURONAL NICOTINIC CHOLINERGIC COMPOUNDS | ABBOTT LABORATORIES (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA3 20/4885CHRNB4 26/4885 |
| US-20100129291-A1 | NICOTINIC DESENSITIZERS AND METHODS OF SELECTING, TESTING, AND USING THEM | CHRNA5, CHRNA2, CHRNA10 | CHRNB2 7/4885CHRNA3 10/4885CHRNB4 11/4885 |
| US-20170107197-A1 | PHENYL-SUBSTITUTED NICOTINIC LIGANDS, AND METHODS OF USE THEREOF | PSEN1, PNMT, OPRL1 | CHRNB2 56/4885CHRNA3 62/4885CHRNB4 36/4885 |
| US-20140323461-A1 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof | PSEN1, PNMT, OPRL1 | CHRNB2 56/4885CHRNA3 62/4885CHRNB4 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.